Abstract
The coronavirus disease 2019 (COVID-19) pandemic led to an abrupt halt of many Alzheimer's disease (AD) research studies at sites spanning the world. This is especially true for studies requiring in-person contact, such as studies collecting biofluids. Since COVID-19 is likely to remain a threat for an extended period, the resumption of fluid biomarker studies requires the development and implementation of procedures that minimize the risk of in-person visits to participants, staff, and individuals handling the biofluid samples. Some issues to consider include structuring the visit workflow to minimize contacts and promote social distancing; screening and/or testing participants and staff for COVID-19; wearing masks and performing hand hygiene; and precautions for handling, storing, and analyzing biofluids. AD fluid biomarker research remains a vitally important public health priority and resuming studies requires appropriate safety procedures to protect research participants and staff.
Original language | English |
---|---|
Pages (from-to) | 27-31 |
Number of pages | 5 |
Journal | Journal of Alzheimer's Disease |
Volume | 76 |
Issue number | 1 |
DOIs | |
State | Published - 2020 |
Bibliographical note
Publisher Copyright:© 2020 - IOS Press and the authors. All rights reserved.
Keywords
- Alzheimer's disease
- COVID-19
- biofluids
- biomarkers
- safety
ASJC Scopus subject areas
- General Neuroscience
- Clinical Psychology
- Geriatrics and Gerontology
- Psychiatry and Mental health